Your browser doesn't support javascript.
loading
Early detection of T-cell lymphoma with T follicular helper phenotype by RHOA mutation analysis.
Dobson, Rachel; Du, Peter Y; Rásó-Barnett, Lívia; Yao, Wen-Qing; Chen, Zi; Casa, Calogero; Ei-Daly, Hesham; Farkas, Lorant; Soilleux, Elizabeth; Wright, Penny; Grant, John W; Rodriguez-Justo, Manuel; Follows, George A; Rashed, Hala; Fabre, Margarete; Baxter, E Joanna; Vassiliou, George; Wotherspoon, Andrew; Attygalle, Ayoma D; Liu, Hongxiang; Du, Ming-Qing.
Afiliação
  • Dobson R; Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge.
  • Du PY; Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge.
  • Rásó-Barnett L; The Haematopathology and Oncology Diagnostic Service, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge.
  • Yao WQ; Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge.
  • Chen Z; Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge.
  • Casa C; The Haematopathology and Oncology Diagnostic Service, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge.
  • Ei-Daly H; The Haematopathology and Oncology Diagnostic Service, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge.
  • Farkas L; The Haematopathology and Oncology Diagnostic Service, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Department of Pathology, Akershus University Hospital, Lorenskog.
  • Soilleux E; Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK; Department of Histopathology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge.
  • Wright P; Department of Histopathology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge.
  • Grant JW; Department of Histopathology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge.
  • Rodriguez-Justo M; Department of Pathology, Royal Free and University College Medical School, London.
  • Follows GA; Department of Haematology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge.
  • Rashed H; Department of Cellular Pathology, University Hospitals of Leicester, East Midlands Pathology Services, Leicester.
  • Fabre M; Wellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Department of Haematology, University of Cambridge, Cambridge.
  • Baxter EJ; Department of Haematology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge.
  • Vassiliou G; Wellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Centre, Department of Haematology, University of Cambridge, Cambridge.
  • Wotherspoon A; Histopathology Department, The Royal Marsden Hospital, London.
  • Attygalle AD; Histopathology Department, The Royal Marsden Hospital, London.
  • Liu H; The Haematopathology and Oncology Diagnostic Service, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge.
  • Du MQ; Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK; Department of Histopathology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge. mqd20@cam.ac.uk.
Haematologica ; 107(2): 489-499, 2022 02 01.
Article em En | MEDLINE | ID: mdl-33567811
ABSTRACT
Angioimmunoblastic T-cell lymphoma (AITL) and peripheral T-cell lymphoma with T follicular helper phenotype (PTCL-TFH) are a group of complex clinicopathological entities that originate from T follicular helper cells and share a similar mutation profile. Their diagnosis is often a challenge, particularly at an early stage, because of a lack of specific histological and immunophenotypic features, paucity of neoplastic T cells and prominent polymorphous infiltrate. We investigated whether the lymphoma-associated RHOA Gly17Val (c.50G>T) mutation, occurring in 60% of cases, is present in the early "reactive" lesions, and whether mutation analysis could help to advance the early diagnosis of lymphoma. The RHOA mutation was detected by quantitative polymerase chain reaction with a locked nucleic acid probe specific to the mutation, and a further peptide nucleic acid clamp oligonucleotide to suppress the amplification of the wild-type allele. The quantitative polymerase chain reaction assay was highly sensitive and specific, detecting RHOA Gly17Val at an allele frequency of 0.03%, but not other changes in Gly17, nor in 61 controls. Among the 37 cases of AITL and PTCL-TFH investigated, RHOA Gly17Val was detected in 62.2% (23/37) of which 19 had multiple biopsies including preceding biopsies in ten and follow-up biopsies in 11 cases. RHOA Gly17Val was present in each of these preceding or follow-up biopsies including 18 specimens that showed no evidence of lymphoma by combined histological, immunophenotypic and clonality analyses. The mutation was seen in biopsies 0-26.5 months (mean 7.87 months) prior to the lymphoma diagnosis. Our results show that RHOA Gly17Val mutation analysis is valuable in the early detection of AITL and PTCL-TFH.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma de Células T / Linfoma de Células T Periférico / Linfadenopatia Imunoblástica Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma de Células T / Linfoma de Células T Periférico / Linfadenopatia Imunoblástica Idioma: En Ano de publicação: 2022 Tipo de documento: Article